Alto Neuroscience Inc. (NYSE: ANRO) is a California-based biopharmaceutical company developing personalised treatments for mental health conditions. It focuses on innovative therapies for major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and schizophrenia, with promising drug candidates like ALTO-100 and ALTO-300. The company is also pioneering a biomarker-based platform to tailor treatments, using patient-specific biological data to improve outcomes. Since its founding in 2019, Alto Neuroscience has been at the forefront of personalised mental health care.
Amazon (AMZN) is set to report its Q1 2025 results after the close on May 1, with investors closely watching how the e-commerce and cloud giant is navigating a more challenging macroeconomic environment.
10:15, 30 April 2025
Read our reviews to find out more about us
Read the feedback from our clients around the world.